Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

19Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: “Do we stop anticoagulants or continue them indefinitely?” The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is “Which anticoagulant?” Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.

Cite

CITATION STYLE

APA

Rodger, M. A., & Le Gal, G. (2018, November 27). Who should get long-term anticoagulant therapy for venous thromboembolism and with what? Blood Advances. American Society of Hematology. https://doi.org/10.1182/bloodadvances.2018020230

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free